Axitinib, Cabozantinib, Everolimus, Nivolumab, Sunitinib and Best Supportive Care in Previously Treated Renal Cell Carcinoma: A Systematic Review and Economic Evaluation
Health Technology Assessment- United Kingdom
doi 10.3310/hta22060
Full Text
Abstract
Available in
Date
January 1, 2018
Authors
Publisher
National Institute for Health Research